{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:09:43Z","timestamp":1693300183349},"reference-count":26,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2017.8244","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T11:35:01Z","timestamp":1512992101000},"source":"Crossref","is-referenced-by-count":2,"title":["c\u2011Jun N\u2011terminal kinase 3 signalling serves a potential role as a biomarker for determining the pathogenesis of Parkinson's disease"],"prefix":"10.3892","author":[{"given":"Xiu\u2011Li","family":"Yang","sequence":"first","affiliation":[{"name":"The Department of Blood Transfusion, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2011Mei","family":"Gao","sequence":"additional","affiliation":[{"name":"The Department of Blood Transfusion, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"key20200713223941_b1-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","article-title":"Pathogenesis-targeted, disease-modifying therapies in Parkinson disease","volume":"11","author":"AlDakheel","year":"2014","journal-title":"Neurotherapeutics"},{"key":"key20200713223941_b2-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","article-title":"Dementia and survival in Parkinson disease: A 12-year population study","volume":"70","author":"Buter","year":"2008","journal-title":"Neurology"},{"key":"key20200713223941_b3-mmr-17-02-3255","volume-title":"Modulation of alpha-synuclein metabolism and toxicity by cathepsin D","author":"Crabtree","year":"2012"},{"key":"key20200713223941_b4-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1056\/NEJM199601113340202","article-title":"Prevalence of parkinsonian signs and associated mortality in a community population of older people","volume":"334","author":"Bennett","year":"1996","journal-title":"N Engl J Med"},{"key":"key20200713223941_b5-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1471-4159.1992.tb09766.x","article-title":"Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease","volume":"58","author":"Kish","year":"1992","journal-title":"J Neurochem"},{"key":"key20200713223941_b6-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0278-5846(89)90121-8","article-title":"Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence","volume":"13","author":"Hornykiewicz","year":"1989","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20200713223941_b7-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.2220","article-title":"Clinical trials of disease-modifying therapies for neurodegenerative diseases: The challenges and the future","volume":"16","author":"Lang","year":"2010","journal-title":"Nat Med"},{"key":"key20200713223941_b8-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/WCO.0b013e3283633741","article-title":"Recent developments in biomarkers in Parkinson disease","volume":"26","author":"Schapira","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"key20200713223941_b9-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrneurol.2011.40","article-title":"Parkinson disease: Parkinson disease clinical subtypes and their implications","volume":"7","author":"Schapira","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"key20200713223941_b10-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"key20200713223941_b11-mmr-17-02-3255","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","article-title":"Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation","volume":"81","author":"Kyriakis","year":"2001","journal-title":"Physiol Rev"},{"key":"key20200713223941_b12-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran","year":"2008","journal-title":"Oncogene"},{"key":"key20200713223941_b13-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/bies.20458","article-title":"The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): Differences revealed by gene targeting","volume":"28","author":"Bogoyevitch","year":"2006","journal-title":"Bioessays"},{"key":"key20200713223941_b14-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/138161211795164095","article-title":"The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A new rodent model to test palliative and neuroprotective agents for Parkinson's disease","volume":"17","author":"Prediger","year":"2011","journal-title":"Curr Pharm Des"},{"key":"key20200713223941_b15-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol"},{"key":"key20200713223941_b16-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1097\/00001756-199412000-00031","article-title":"Immunohistochemical evidence for apoptosis in Alzheimer's disease","volume":"5","author":"Su","year":"1994","journal-title":"Neuroreport"},{"key":"key20200713223941_b17-mmr-17-02-3255","doi-asserted-by":"crossref","unstructured":"TowbinHStaehelinTGordonJElectrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applicationsProc Natl Acad Sci USA7643504354197910.1073\/pnas.76.9.4350388439411572","DOI":"10.1073\/pnas.76.9.4350"},{"key":"key20200713223941_b18-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1023\/B:BIRY.0000040215.02460.45","article-title":"JNK: A key modulator of intracellular signaling","volume":"69","author":"Vlahopoulos","year":"2004","journal-title":"Biochemistry (Mosc)"},{"key":"key20200713223941_b19-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"key20200713223941_b20-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev.physiol.60.1.601","article-title":"Cell cycle regulation and apoptosis 1","volume":"60","author":"King","year":"1998","journal-title":"Annu Rev Physiol"},{"key":"key20200713223941_b21-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s002340100558","article-title":"Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy","volume":"43","author":"Hanyu","year":"2001","journal-title":"Neuroradiology"},{"key":"key20200713223941_b22-mmr-17-02-3255","unstructured":"DonovanSParkinson's disease treatmentUS 6620415 B2Filed July 11, 2001; issued September 162003"},{"key":"key20200713223941_b23-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11910-009-0058-x","article-title":"Gray matter pathology and multiple sclerosis","volume":"9","author":"Wegner","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"key":"key20200713223941_b24-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.2741\/3872","article-title":"Role of Rho GTPases and their regulators in cancer progression","volume":"16","author":"Rathinam","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"key20200713223941_b25-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/0008-5472.CAN-11-1628","article-title":"Role of JNK in mammary gland development and breast cancer","volume":"72","author":"Cellurale","year":"2012","journal-title":"Cancer Res"},{"key":"key20200713223941_b26-mmr-17-02-3255","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.1995.0002","article-title":"Cell death in health and disease: The biology and regulation of apoptosis","volume":"6","author":"Bellamy","year":"1995","journal-title":"Semin Cancer Biol"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:59:13Z","timestamp":1660107553000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.8244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":26,"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.8244","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]}}}